

University of Groningen

Revisiting co-trimoxazole for the treatment of tuberculosis

Alsaad, Noor Sabah Idan

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Alsaad, N. S. I. (2016). *Revisiting co-trimoxazole for the treatment of tuberculosis*. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

STELLINGEN

behorend bij het proefschrift

Revisiting Co-trimoxazole for the treatment of tuberculosis

door

Noor Alsaad

- I. While developing new anti-TB drugs is critically important, old, cheap and safe drugs like co-trimoxazole may be equally important to reach the Sustainable Development Goals to overcome TB by 2035 (this thesis).
- II. An old drug like co-trimoxazole is rarely included in PK and PD studies, and therefore, an update is required (this thesis).
- III. While we need PK/PD targets for co-trimoxazole in TB, the PK/PD targets for its labeled indication have not even been defined (this thesis).
- IV. To perform therapeutic drug monitoring in remote settings, one needs easy sample collection and transportation (this thesis).
- V. The PK variability of co-trimoxazole in patients with drug-susceptible TB is high, much higher than the PK variability for co-trimoxazole in patients with MDR-TB (this thesis)
- VI. Acquired drug resistance in TB is man-made; as it is our own fault, we should also prevent it by PK/PD guided dosing.
- VII. There is no significant difference in susceptibility of *M. tuberculosis* to co-trimoxazole between TB-patients without co-infection, and those co-infected with HIV (this thesis).
- VIII. In patients dually infected with TB and HIV, co-trimoxazole should always be combined with anti-TB drugs, irrespective of CD4+ count.
- IX. Life is like riding a bicycle: to keep your balance, you must keep moving (Albert Einstein).
- X. Everything happens for a reason (my mother).
- XI. The roots of education are bitter but the fruit is sweet (Aristotle).
- XII. The final forming of a person's character lies in their own hands (Anne Frank).
- XIII. Turn your face to the sun and the shadows fall behind you (Maori Proverb).

